Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rhabdomyosarcoma × Ifosfamide × Clear all

Phase

Status

Completed 7 Terminated 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 5 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, B-Cell 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Penile Neoplasms 2 Osteosarcoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Burkitt Lymphoma 2 Wilms Tumor 1 Vascular Neoplasms 1 Teratoma 1 Solitary Fibrous Tumors 1 Smooth Muscle Tumor 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Rhabdomyosarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pleuropulmonary blastoma 1 Neurofibrosarcoma 1 Neuroblastoma 1 Nerve Sheath Neoplasms 1 Neoplasms, Adipose Tissue 1 Neoplasm Metastasis 1 Myoepithelioma 1 Lymphoma, Follicular 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myelomonocytic, Chronic 1

Interventions

Temozolomide 7 Cyclophosphamide 6 Vincristine 5 fludarabine 4 pegfilgrastim 2 irinotecan sucrosofate 2 fludarabine phosphate 2 Zoledronic Acid 2 Vinorelbine 2 Irinotecan 2 Filgrastim 2 Dactinomycin 2 talazoparib 1 silmitasertib 1 regorafenib 1 pegylated granulocyte colony-stimulating factor 1 pazopanib 1 liposomal doxorubicin 1 cabozantinib 1 amino-acid, glucose, and electrolyte solution 1 Whole-Body Irradiation 1 Tacrolimus 1 Radiotherapy 1 Mesna 1 Melphalan 1 Influenza Vaccines 1 Indocyanine Green 1 Immunotherapy, Adoptive 1 Immune Checkpoint Inhibitors 1 Ifosfamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡